Cadila Healthcare's shares fell as much as 3.6 per cent to Rs 292.85. The stocks had touched a four-year low.
The United States Food and Drug Administration (USFDA) inspected the company’s formulations manufacturing facility at Moraiya as well Ahmedabad from April 22 to May 3 and concluded the inspection with 14 observations, the company said on Friday.
Moraiya is Cadila Healthcare’s largest manufacturing facility for the US market and the FDA's issuance of 14 observations may act as an overhang, Investec said.
The shares were down 12.8 per cent as of the last close.